Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

ADC Therapeutics and BZL Biologics Announces Licensing and Collaboration Agreement

Published: Tuesday, July 16, 2013
Last Updated: Monday, July 15, 2013
Bookmark and Share
Company licenses proprietary antibody from BZL Biologics for prostate cancer.

ADC Therapeutics Sarl and BZL Biologics LLC have announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

PSMA is a cell-surface antigen on prostate cancer cells, and PSMA levels correlate directly with an aggressive, metastasizing phenotype.

The characteristics of PSMA - its cancer specificity, presence in 95% of prostate cancers, high level of expression, and rapid internalization - make it an ideal ADC target.

ADC Therapeutics plans to initiate pre-IND development of a PSMA-specific ADC immediately, adding to ADC Therapeutics’ portfolio of proprietary ADC programs.

Its unique platform combines monoclonal antibodies specific to particular types of tumor cells, in this case PSMA, with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads.

As ADC Therapeutics PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.

Dr Neil H. Bander, Director of Urological Oncology Research at Weill Cornell Medical College from where the anti-PSMA antibody was licensed, said: “We have direct experience with virtually every antibody-drug conjugate platform currently available; none have produced the level of efficacy we have seen with ADC Therapeutics’ PBD warheads - in vivo efficacy data from their PSMA-targeted ADC drug candidate are truly exciting, and we are excited to see this potentially breakthrough therapy translated into a clinic program as soon as possible.”

Dr. Peter B. Corr, Chairman of ADC Therapeutics and Managing General Partner of Auven Therapeutics, said: “Having the technology platform to develop novel ADCs against important cancer targets and transform healthcare outcomes for patients is a critical part of what we are building at ADC Therapeutics. We are pleased to have established this exclusive relationship with the outstanding team in Dr. Bander’s laboratories at Weill-Cornell.”

Financial terms were not disclosed and remain confidential.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ADC Therapeutics Expands Team
Company’s lead program, ADCT-301, to enter clinical development in early 2015.
Wednesday, October 08, 2014
Prostrate Cancer Drug Moves into Human Clinical Trials
ADC Therapeutics announced that it has selected its first IND candidate under its joint development agreement with MedImmune.
Monday, May 19, 2014
ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics
Adds an additional proprietary ADC development program in oncology.
Thursday, November 07, 2013
VivaMab and ADC Therapeutics Announce Antibody Licensing Deal
VivaMab and ADC Therapeutics Sarl announced a licensing deal for a novel antibody against an undisclosed hematological cancer target.
Tuesday, June 25, 2013
Scientific News
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos